Back to Search
Start Over
Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.
- Source :
- Journal of Gastrointestinal Cancer; Sep2024, Vol. 55 Issue 3, p1448-1452, 5p
- Publication Year :
- 2024
-
Abstract
- Purpose: Treatment of metastatic pancreatic neuroendocrine tumors (pancNETs), particularly grade 2 (G2) and grade 3 (G3), often presents a dilemma in choosing from multiple similarly efficacious therapies. Data on targeted therapies for these tumor types is limited, and this report presents BRAF-targeted therapy as a therapeutic option for metastatic pancNET G3. Methods: This is a case report of a patient with G3 pancNET metastatic to the liver, lung, lymph node, and scalp (soft tissue) treated with dabrafenib/trametinib (D/T) in the presence of a BRAF V600E mutation detected in tumor tissue. Results: This patient has demonstrated an ongoing partial response to therapy at all involved sites for nearly 15 months with minimal side effects attributable to D/T. Conclusion: Dabrafenib/trametinib therapy for BRAF-mutated metastatic pancNETs provides a novel treatment option and, especially in the G3 setting, should be considered a first-line option. Tumor testing for actionable mutations should be undertaken at the time of diagnosis and/or progression to identify novel therapeutic avenues in these rare tumors. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 19416628
- Volume :
- 55
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Journal of Gastrointestinal Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 179258059
- Full Text :
- https://doi.org/10.1007/s12029-024-01072-0